TheraBreath is debuting a new whitening rinse that is not only gentle on teeth but tough on unsightly stains.
New from the brand is the Dazzling Mint Whitening Rinse, which the company attacks discoloration with solubilizers that loosen stains. It contains a natural enzyme that works with saliva to dissolve stains and has an oxidizer to whiten teeth, the company said.
In addition, the rinse also forms a protective barrier that helps to resist and defend against common sources of stains such as coffee, tea and wine.
Retailing for $10.95, TheraBreath’s Dazzling Mint Whitening Rinse is available for purchase online and at major retailers nationwide.
RxBar is kicking off fall a little early by releasing three of its popular seasonal flavors for a limited time.
The Chicago-based company shared that its pumpkin spice, pecan and gingerbread flavors, which were inspired by decadent delights and smells, contain egg whites for 12 g of protein, dates to bind and nuts for texture.
“The back half of the year, especially the last few months, can be filled with a variety of B.S. that our fans have to manage,” said Carly Smith, senior associate brand manager for RxBar. “These bars are anything but basic, and we hope each nostalgic flavor helps eliminate any added stress or drama the season might bring along.”
Priced at $2.79 per bar, $9.99 per 4-pack and $25.99 for a 12-pack, RxBar’s pumpkin spice flavor is now available for purchase online and at select retail stores nationwide. The gingerbread and pecan bars will be available for purchase beginning Sept. 20.
Rafa has obtained the Food and Drug Administration’s clearance for its 10 mg midazolam auto-injector for the treatment of status epilepticus in adults.
The Midazolam 10 mg auto-injector is indicated for the treatment of status epilepticus, or prolonged seizures, in adults. As such, this new auto-injector can be used to treat seizures resulting from nerve agent exposure. According to the U.S. JPEO-CBRND, the auto-injector will replace the currently fielded convulsant antidote for the nerve agent diazepam autoinjector.
Rafa’s innovation resides in the use of an auto-injector to be administered intramuscularly to the thigh (can be administered through clothes as well), in a manner that does not require an intravenous line. This is a significant advantage in a field setting during an emergency when fast treatment reduces the likelihood of permanent damage that could result from a continuous seizure, the company said.
“We are proud of the FDA approval for this lifesaving product,” said Amir Levin, CEO of Rafa. “It is made in Israel and is meaningful news to the world of medical emergency solutions, thus strengthening Rafa’s key role in providing reliable products to armies, governments and first responders worldwide.”
The product is made at Rafa’s manufacturing site in Jerusalem and is already sold under EUA in other territories.
“The usability of the auto-injector has a significant medical advantage in its immediate treatment effect, as well as in reducing long-term damage,” said Roy Shay, head of emergency solutions at Rafa. “Clinical studies confirmed the correlation between early treatment of status epilepticus and a reduced risk of an ongoing and irreversible neurological damage. This product could assist in saving many lives around the globe.”
NACDS announces 2022 Total Store Expo showcase winners
The National Association of Chain Drug Stores has announced the winners of the 2022 Total Store Expo Product Showcase.
Products ranging from home health care to baby care and household products were on display in the Product Showcase on the exhibit floor — which provided increased visibility for suppliers to market their products to retailers.
Evaluated by the retail attendees, the winners of this year’s Product Showcase are:
Company: Xtreme Beauty International / OKAY
Name of Product: OKAY Baby Care
Company: E.&J. Gallo Winery
Name of Product: High Noon Seltzers Tailgate Pack
Cosmetics & Fragrances:
Company: Kiss Products
Name of Product: Kiss Falscara
Company: American Greetings
Name of Product: Magic Moments by American Greetings
Company: Liquid I.V.
Name of Product: Liquid I.V. Energy Multiplier — Yuzu Pineapple
Home Health Care:
Company: Gateway Genomics
Name of Product: SneakPeek Early Gender DNA Test
Household Products/Non-Edible Consumables:
Name of Product: LooLoo Touchless Toilet Spray
Company: GESKE Beauty Tech GmbH
Name of Product: SmartAppGuided Skincare Products
Pharmacy Operations Equipment and Services:
Name of Product: ScriptSave Personalized Wellness Healthcare
NACDS congratulated the winners of the 2022 Showcase and thanked the myriad participants whose new merchandising ideas and products made the event even more valuable for meeting attendees.
FDA gives Incyte approval for new Pemazyre indication
Incyte has received the Food and Drug Administration’s clearance for Pemazyre (pemigatinib), a selective fibroblast growth factor receptor inhibitor.
The medication is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
“The approval of Pemazyre represents an important treatment advancement for people living with MLNs with FGFR1 rearrangement who currently have limited treatment options,” said Hervé Hoppenot, CEO of Incyte. “These are complex hematologic malignancies with a range of presentations, and this approval highlights Incyte’s continued leadership and commitment to advancing care for patients with rare blood cancers.”
MLNs with FGFR1 rearrangement are extremely rare and aggressive blood cancers that may impact less than 1 in 100,000 people in the United States, the company noted.
“In patients with relapsed or refractory MLNs with FGFR1 rearrangement treated with Pemazyre in FIGHT-203, the high rate of complete response and complete cytogenetic response in patients with chronic phase disease and the high rate of complete cytogenetic response in patients with blast phase disease is clinically meaningful, especially in light of the lack of these specific responses with existing first-line treatments,” said Srdan Verstovsek, professor, department of Leukemia, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center and principal investigator for the FIGHT-203 study.
Pemazyre, a fibroblast growth factor receptor inhibitor, is the first targeted treatment approved for use in the United States for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Pemazyre also is indicated for the treatment of adults with relapsed or refractory previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on the overall response rate and duration of response. Continued approval may be contingent on verification and description of clinical benefit in a confirmatory trial(s).
Nütrl launches cranberry vodka seltzers in variety pack